Neurologia

M-A | Prevalência global da condição pós-COVID-19 ou COVID longa.

21 Abr, 2022 | 11:37h

Global Prevalence of Post COVID-19 Condition or Long COVID: A Meta-Analysis and Systematic Review – The Journal of Infectious Diseases

Comentário: Global data reveal half may have long COVID 4 months on – CIDRAP

 

Comentário no Twitter (fio – clique para saber mais)

🚨The so far largest meta-analysis of more than 1.5 million infected individuals puts the global prevalence of #LongCovid at 43%. Some additional key findings. 🧵https://t.co/XGu23MV3Ra
1/

— Jonas R. Kunst (@KunstJonas) April 17, 2022

 

---

Estudo de coorte | Associação do tratamento com antipsicóticos, antidepressivos ou ambos com transtornos do movimento e convulsões entre crianças e adolescentes com depressão.

21 Abr, 2022 | 11:26h

Association of Treatment With Antipsychotics, Antidepressants, or Both With Movement Disorders and Seizures Among Children and Adolescents With Depression in Korea – JAMA Network Open

 

Comentário no Twitter

In this cohort study, adjunctive antipsychotics with antidepressants were associated with movement disorders and seizures compared with antidepressant monotherapy in children and adolescents with depression. https://t.co/3SVKEThwkR

— JAMA Network Open (@JAMANetworkOpen) April 15, 2022

 

---

Cuidado paliativo para idosos com demência – Precisamos de uma mudança de paradigma em nossa abordagem – “A diretriz avançada de cuidado (advance care planning – ACP) é o princípio de um bom cuidado paliativo na demência.”

21 Abr, 2022 | 11:16h

Palliative care for older people with dementia—we need a paradigm shift in our approach – Age and Ageing

---

Estudo randomizado | Segurança e eficácia da ganaxolona em pacientes com distúrbio da deficiência de CDKL5.

20 Abr, 2022 | 14:53h

Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial – The Lancet Neurology (link para o resumo – $ para o texto completo)

---

Um estudo randomizado controlado explorou a segurança e a tolerabilidade do sultiame na apneia do sono.

19 Abr, 2022 | 12:28h

A Randomized Controlled Trial Exploring Safety and Tolerability of Sulthiame in Sleep Apnea – American Journal of Respiratory and Critical Care Medicine

Comunicado de imprensa: Drug reduced frequency of breathing pauses in sleep apnea – University of Gothenburg

 

Comentário no Twitter

In a four-week trial of patients with OSA not tolerating PAP therapy, researchers found that the carbonic anhydrase inhibitor sulthiame reduced OSA by more than 20 events per hour, one of the strongest reductions reported in a drug trial in OSA. https://t.co/EizlbFbvFm pic.twitter.com/DxylRQR4Pa

— American Academy of Sleep Medicine (@AASMorg) February 28, 2022

 

---

Prevalência global da cefaleia: atualização com análise das influências de fatores metodológicos sobre as estimativas de prevalência.

19 Abr, 2022 | 12:25h

The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates – The Journal of Headache and Pain

Comunicado de imprensa: Global estimates of headaches suggest disorder impacts over 50 percent of the population – BMC

---

Estudo transversal | Uso de inibidores seletivos de recaptação de serotonina está associado com redução de movimentos medidos.

18 Abr, 2022 | 15:20h

Association of Selective Serotonin Reuptake Inhibitor Use With Abnormal Physical Movement Patterns as Detected Using a Piezoelectric Accelerometer and Deep Learning in a Nationally Representative Sample of Noninstitutionalized Persons in the US – JAMA Network Open

 

Comentário no Twitter

This cross-sectional study found SSRI use was associated with a reduction in measured movements, highlighting the utility of passively collected data for exploring and characterizing adverse drug effects. https://t.co/54ZngDdt8u

— JAMA Network Open (@JAMANetworkOpen) April 7, 2022

 

---

Estudo de coorte de base populacional | Estilo de vida saudável e expectativa de vida com e sem demência de Alzheimer.

18 Abr, 2022 | 15:17h

Healthy lifestyle and life expectancy with and without Alzheimer’s dementia: population based cohort study – The BMJ

Editorial: Healthy lifestyles and more life years without dementia – The BMJ

 

Comentário no Twitter

A new US study suggests that a healthy lifestyle is associated with a longer life expectancy among both men and women, and they lived a larger proportion of their remaining years without Alzheimer’s diseasehttps://t.co/eXsQRd6mon

— The BMJ (@bmj_latest) April 14, 2022

 

---

Novas descobertas sobre a etiologia genética da doença de Alzheimer e demências relacionadas.

14 Abr, 2022 | 17:36h

New insights into the genetic etiology of Alzheimer’s disease and related dementias – Nature Genetics

Comunicado de imprensa: Landmark study reveals 42 new genes associated with increased risk of Alzheimer’s disease – UK Dementia Research Institute

Comentários:

42 previously unknown genes discovered for Alzheimer’s disease – CNN

Alzheimer’s disease research takes ‘major leap forward’ – BBC

Expert reaction to study of genes associated with increased risk of Alzheimer’s – Science Media Centre

 

Comentário no Twitter

A meta-analysis in @NatureGenet of genome-wide association studies on Alzheimer’s disease and related dementias identifies new loci and enables generation of a new genetic risk score associated with the risk of future Alzheimer’s disease and dementia. https://t.co/EAtdlRozld pic.twitter.com/5rtWWt4HyS

— Nature Portfolio (@NaturePortfolio) April 11, 2022

 

---

Síntese das evidências | Tratamento pré-hospitalar e no departamento de emergência do estado epiléptico convulsivo em adultos.

14 Abr, 2022 | 17:29h

Pre-hospital and emergency department treatment of convulsive status epilepticus in adults: an evidence synthesis – Health Technology Assessment

---